|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
April 2006FeaturesCover Story Copayments: Too Much, Yet Not Enough?Introduced to sensitize people to the cost of prescription drugs, copayments may be archaic in the era of
biologic therapies. The risk is great that high copayments for specialty drugs effectively become a denial of possibly life-saving care. Regulatory The Off-Label ConundrumOff-label use is proliferating, a development watched carefully by payers, physicians, and biotechs. Issues include costs, potential for unwanted side effects, and legal ramifications. Diagnostics Ultrasensitive Measurement of Protein and Nucleic Acid Biomarkers for Earlier Disease Detection and More Effective TherapiesClinical decision making stands to benefit from ultrasensitive molecular diagnostic tools that identify disease-related changes in biomarker levels before advanced
clinical signs and symptoms manifest. Clinical Emerging Therapies Offer New Methods For Treating Rheumatoid ArthritisThe approvals of abatacept and rituximab have invigorated the already competitive market for biologic RA treatments. The new generation of RA therapies now reaching the market presents opportunities for patients — and challenges for payers. Leading Edge The Cancer Genome Atlas: New Weapon in Old War?The latest salvo in the War on Cancer is a program to explore the feasibility of producing the Cancer Genome Atlas, with the expectation of improved therapies to follow. Though noble, the effort will be time- and labor-intensive, raising the question of whether a prolonged application of preventive measures would ultimately prove to be more effective than resource-consuming molecule-to-molecule combat. DepartmentsOpeners 2006: The State of BiologicsGuest essay by Katherine T. Adams: The state of biologics in 2006. Editorial Ready to Rumble?The lack of knowledge about biotech troubles David B. Nash, MD, MBA. Washington Watch Global Deals Grow; So Do Regulatory IssuesThe financial sense behind international drug-development partnerships. Diagnostics and Devices Pooling Resources to Improve Cancer ResearchPooling sample size improves results. DrugTrack Approvals, FDA Actions, Clinical TrialsBiotech Business Conflicts of Interest Threaten BiotechAvoiding conflicts of interest. Trends Biotech Products Go Blockbuster
Katherine T. Adams |
|||||